Fungal Infectious Disease disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: FNG017 MIFTS: 55	Fungal Infectious Disease Categories: Infectious diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Fungal Infectious Disease

MalaCards integrated aliases for Fungal Infectious Disease:

Name: Fungal Infectious Disease ¹¹ ¹⁴

Mycoses ¹¹ ⁴³ ¹⁴ ³¹ ³³

Mycosis ¹¹

Classifications:

MalaCards categories:
Global: Infectious diseases

See all MalaCards categories (disease lists)

ICD10: ³¹

Certain infectious and parasitic diseases

Mycoses

Other mycoses, not elsewhere classified

Other specified mycoses

Unspecified mycosis

ICD11: ³³

Certain infectious or parasitic diseases

Mycoses

Mycoses, unspecified

Other specified mycoses

External Ids:

Disease Ontology ¹¹ DOID:1564

ICD9CM ³⁴ 110-118.99

MeSH ⁴³ D009181

NCIt ⁴⁹ C3245

SNOMED-CT ⁶⁸ 154393000

ICD10 ³¹ B35-B49 B48.8 B49

ICD11 ³³ 1939815950 1939815950/other 1939815950/unspecified

UMLS ⁷¹ C0026946

Sources

Summaries for Fungal Infectious Disease

Disease Ontology: ¹¹ A disease by infectious agent that results in infection, has material basis in Fungi, which pass the resistance barriers of the human or animal body.

MalaCards based summary: Fungal Infectious Disease, also known as mycoses, is related to sezary's disease and primary cutaneous t-cell non-hodgkin lymphoma. An important gene associated with Fungal Infectious Disease is CCR6 (C-C Motif Chemokine Receptor 6), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Voriconazole and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include skin, liver and t cells, and related phenotypes are homeostasis/metabolism and immune system

Sources

Related Diseases for Fungal Infectious Disease

Diseases related to Fungal Infectious Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1482)

#	Related Disease	Score	Top Affiliating Genes
1	sezary's disease	32.5	IL4 IL10 CD8A CD4 CCR6
2	primary cutaneous t-cell non-hodgkin lymphoma	32.5	IL4 H2AC18 CD4 CCR6
3	superficial mycosis	32.3	CLEC7A CLEC6A CD4 CCR6 CARD9
4	subcutaneous mycosis	32.1	TLR2 IL17A IL10 CLEC7A CLEC6A CD4
5	histoplasmosis	32.1	TNF CLEC7A CLEC6A CD4 CCR6
6	primary systemic mycosis	31.9	TNF TLR2 IL6 IL4 IL1B IL17A
7	coccidioidomycosis	31.8	IL17A CYP51A1 CLEC7A CLEC6A CD4 CCR6
8	sporotrichosis	31.8	TNF IL10 CLEC7A CLEC6A CD4 CARD9
9	chromoblastomycosis	31.8	IL4 CLEC7A CLEC6A CCR6 CARD9
10	paracoccidioidomycosis	31.7	TNF TLR2 IL6 IL4 IL10
11	pityriasis versicolor	31.7	CLEC7A CLEC6A CCR6 CARD9
12	cryptococcosis	31.6	TNF IL4 IL17A IL10 CYP51A1 CLEC7A
13	opportunistic mycosis	31.6	TNF TLR2 IL6 IL4 IL1B IL17RA
14	mucormycosis	31.6	TNF IL6 IL10 CYP51A1 CRP CLEC7A
15	dermatophytosis	31.6	TNF IL1B IL17F IL17A CYP51A1 CLEC7A
16	parapsoriasis	31.5	CD8A CD4
17	tinea corporis	31.5	CLEC7A CLEC6A CD4 CARD9
18	tinea pedis	31.5	IL17A CYP51A1 CLEC7A CLEC6A CD4 CCR6
19	blastomycosis	31.5	TNF IL6 IL17A CYP51A1 CRP CLEC7A
20	follicular mucinosis	31.5	CD8A CD4
21	tinea capitis	31.5	CYP51A1 CLEC7A CLEC6A CD4 CARD9
22	phaeohyphomycosis	31.5	CLEC7A CLEC6A CARD9
23	tinea cruris	31.3	CYP51A1 CLEC6A CARD9
24	actinomycosis	31.3	TNF IL10 CRP CD4
25	tinea unguium	31.3	CYP51A1 CRP CARD9
26	acquired immunodeficiency syndrome	31.3	TNF IL6 IL1B IL10 CRP CD4
27	tinea imbricata	31.2	CLEC7A CLEC6A CARD9
28	penicilliosis	31.1	CLEC7A CD4 CARD9
29	granuloma annulare	31.1	TNF IL17A CD8A CD4
30	peripheral t-cell lymphoma	31.1	ICOSLG H2AC18 CD8A CD4 CCR6
31	lymphoma, non-hodgkin, familial	31.1	IL6 ICOSLG H2AC18 CD8A CD4 CCR6
32	dermatitis	31.0	TNF IL6 IL4 IL1B IL17A IL10
33	invasive aspergillosis	31.0	TNF TLR2 IL6 IL17A IL10 CYP51A1
34	vitiligo-associated multiple autoimmune disease susceptibility 1	31.0	TNF IL17A ICOSLG CD8A CD4 CCR6
35	meningitis	31.0	TNF TLR2 IL6 IL4 IL1B IL17A
36	neutropenia	31.0	TNF IL6 IL4 IL1B IL10 CRP
37	pneumocystosis	30.9	TNF IL6 IL17A IL10 CRP CLEC7A
38	spongiotic dermatitis	30.9	CD8A CD4 CCR6
39	lichen planus	30.9	TNF IL6 IL4 IL1B IL17A IL10
40	t-cell adult acute lymphocytic leukemia	30.9	CD8A CD4 CCR6
41	panniculitis	30.9	CRP CD8A CD4 CCR6
42	basal cell carcinoma	30.9	TNF IL6 ICOSLG H2AC18 CCR6
43	oral candidiasis	30.8	IL6 IL17RA IL17F IL17A CLEC7A CLEC6A
44	dermatomycosis	30.8	CYP51A1 CD4 CARD9
45	angioimmunoblastic t-cell lymphoma	30.8	ICOSLG CD8A CD4 CCR6
46	nocardiosis	30.8	TNF CRP CD4
47	leukemia, chronic lymphocytic	30.8	TNF IL6 IL4 IL10 ICOSLG H2AC18
48	telangiectasis	30.8	TNF H2AC18 CCR6
49	alopecia areata	30.8	TNF IL6 IL4 IL1B IL17A ICOSLG
50	histiocytosis	30.8	TNF IL4 IL17A CCR6

Graphical network of the top 20 diseases related to Fungal Infectious Disease:

Sources

Symptoms & Phenotypes for Fungal Infectious Disease

MGI Mouse Phenotypes related to Fungal Infectious Disease:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.31	AIRE CARD9 CCR6 CD4 CLEC7A CRP
2	immune system	MP:0005387	10.3	AIRE CARD9 CCR6 CD4 CD8A CLEC6A
3	digestive/alimentary	MP:0005381	10.11	AIRE CD4 CLEC7A CYP51A1 IL10 IL17A
4	no phenotypic analysis	MP:0003012	10.09	AIRE CD4 CLEC6A CYP51A1 IL10 IL17A
5	hematopoietic system	MP:0005397	10.09	AIRE CARD9 CCR6 CD4 CD8A CLEC6A
6	neoplasm	MP:0002006	10	AIRE IL10 IL17RA IL1B IL6 TLR2
7	respiratory system	MP:0005388	9.96	AIRE CLEC7A IL10 IL17A IL17F IL17RA
8	mortality/aging	MP:0010768	9.8	AIRE CD4 CD8A CLEC6A CLEC7A CYP51A1
9	integument	MP:0010771	9.32	CD4 CD8A IL10 IL17A IL17RA IL1B

Sources

Drugs & Therapeutics for Fungal Infectious Disease

Drugs for Fungal Infectious Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 305)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Voriconazole

Approved

Phase 4

137234-62-9

71616

Miconazole

Approved, Investigational, Vet_approved

Phase 4

22916-47-8

4189

Clotrimazole

Approved, Vet_approved

Phase 4

23593-75-1

2812

Ibuprofen

Approved

Phase 4

15687-27-1

3672

Anidulafungin

Approved, Investigational

Phase 4

166663-25-8

166548

Amphotericin B

Approved, Investigational

Phase 4

1397-89-3

5280965

Sargramostim

Approved, Investigational

Phase 4

123774-72-1

Dimethyl sulfoxide

Approved, Vet_approved

Phase 4

67-68-5

679

Denileukin diftitox

Approved, Investigational

Phase 4

173146-27-5

Nystatin

Approved, Vet_approved

Phase 4

1400-61-9

11953884

Isavuconazole

Approved, Investigational

Phase 4

241479-67-4

21937662

Itraconazole

Approved, Investigational

Phase 4

84625-61-6

55283

Posaconazole

Approved, Investigational, Vet_approved

Phase 4

171228-49-2

147912

Levoleucovorin

Approved, Experimental, Investigational

Phase 4

68538-85-2, 58-05-9, 73951-54-9

149436 6006

Micafungin

Approved, Investigational

Phase 4

235114-32-6

477468

Methotrexate

Approved

Phase 4

1959-05-2, 59-05-2

4112 126941

Folic acid

Approved, Nutraceutical, Vet_approved

Phase 4

59-30-3

6037

Molgramostim

Investigational

Phase 4

99283-10-0

Anti-Infective Agents

Phase 4

Hormones

Phase 4

Hormone Antagonists

Phase 4

Antifungal Agents

Phase 4

Cytochrome P-450 Enzyme Inhibitors

Phase 4

Cytochrome P-450 CYP3A Inhibitors

Phase 4

Cyclooxygenase Inhibitors

Phase 4

Anti-Inflammatory Agents, Non-Steroidal

Phase 4

Echinocandins

Phase 4

Liposomal amphotericin B

Phase 4

Amebicides

Phase 4

Ionophores

Phase 4

Liver Extracts

Phase 4

Hydroxyitraconazole

Phase 4

108222

Folic Acid Antagonists

Phase 4

Folate

Phase 4

Vitamin B9

Phase 4

Vitamin B Complex

Phase 4

Pharmaceutical Solutions

Phase 4

Interferon alpha-2

Phase 4

Interferon-alpha

Phase 4

interferons

Phase 4

Clorazepate Dipotassium

Phase 4

Tolnaftate

Approved, Investigational, Vet_approved

Phase 3

2398-96-1

5510

Doxycycline

Approved, Investigational, Vet_approved

Phase 3

564-25-0

54671203

Fluconazole

Approved, Investigational

Phase 3

86386-73-4

3365

Caspofungin

Approved

Phase 3

179463-17-3, 162808-62-0

2826718

Doripenem

Approved, Investigational

Phase 3

148016-81-3

73303

Rifabutin

Approved, Investigational

Phase 3

72559-06-9

46783538 6323490

Azithromycin

Approved

Phase 3

83905-01-5

447043

Betamethasone

Approved, Vet_approved

Phase 3

378-44-9

9782

Dexamethasone acetate

Approved, Investigational, Vet_approved

Phase 3

1177-87-3

3680

Interventional clinical trials:

(show top 50) (show all 529)

#	Name	Status	NCT ID	Phase	Drugs
1	Efficacy and Safety in Micafungin Sodium for Prophylaxis Against Invasive Fungal Disease During Neutropenia in Pediatric & Adolescent Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation	Unknown status	NCT01135589	Phase 4	Micafungin
2	Safety of Fluconazole Treatment of Premature and Full-term Newborn Infants - A Study on Interactions by Nonsteroidal Anti Inflammatory Drugs (NSAIDs) With Fluconazole in Respect of Pharmacodynamic Endpoints With Urinary Excretion of Vasoactive Endobiotics	Completed	NCT02079298	Phase 4	Treatment with fluconazole.;2. Treatment with both fluconazole and Ibuprofen.;3. Treatment with ibuprofen.
3	Pharmacokinetics of Caspofungin After One Dose in Patients With Liver Failure	Completed	NCT01968395	Phase 4	Caspofungin 70 mg
4	Anidulafungin Versus Fluconazole for the Prevention of Invasive Fungal Infections in High-risk Liver Transplant Recipients: a Randomized, Double-blind Trial	Completed	NCT00841971	Phase 4	Anidulafungin;Fluconazole
5	Clinical Study to Evaluate the Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation for Pediatric Solid Tumors	Completed	NCT00336531	Phase 4	itraconazole
6	Effect of Granulocyte-macrophage Stimulating Factor on Prevention and Treatment of Invasive Fungal Diseases in the Recipients of Allogeneic Stem Cell Transplantation: A Prospective Multicenter Randomized Phase 4 Trial	Completed	NCT01232504	Phase 4	rhGM-CSF group;rhG-CSF+rhGM-CSF group;rhG-CSF group
7	Population Pharmacokinetic Analysis of Anidulafungin in Normal, Overweight and Obese Volunteers	Completed	NCT01307930	Phase 4	Anidulafungin
8	Fluconazole Pharmacokinetics, Including Bioavailability, in Obese Subjects After an Intravenous and Oral Administration (FOLIA)	Completed	NCT04122560	Phase 4	Fluconazole 200mg tab;Fluconazole 2 MG/ML
9	Comparison of Effectiveness of Topical Amphotericin B in 30% Dimethylsulphoxide and 30% Dimethylsulphoxide in Treating of Non-dermatophytes Onychomycosis: Randomized Double Blind Controlled Trial Pilot Study	Completed	NCT03814343	Phase 4	amphotericin B in 30% DMSO;30% DMSO
10	Single Dose Population Pharmacokinetics of Intravenous Posaconazole in Critically Ill Patients	Completed	NCT02968134	Phase 4	Posaconazole
11	An Open Label, Non-comparative, Multicenter Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infection	Completed	NCT00647907	Phase 4	Voriconazole
12	A Randomized Controlled Trial of the Effect of Cytochrome P450 2C19 Genotype-Specific Dosing Plus TDM vs. TDM Alone on Reaching Therapeutic Voriconazole Blood Levels	Completed	NCT03731169	Phase 4	Standard of Care
13	ANTIVORIFUNGOL:Strategy of Antifungal Use in Oncohematological Neutropenic Patients. Use of Voriconazole as Early Treatment.	Completed	NCT00386802	Phase 4	Antifungal drug. VORICONAZOL. (VFEND®)
14	A Phase 4 Study of the Pharmacokinetics of Oral Posaconazole (SCH 56592) Among Patients With Compromised Gastrointestinal Function and at High Risk for Invasive Fungal Infection	Completed	NCT00686543	Phase 4	Posaconazole
15	Prospective, Open-Label, Non-Comparative, Multicenter Study for the Secondary Prophylaxis of Invasive Fungal Infections (IFI) With Voriconazole in Patients With Allogeneic Stem Cell Transplants (SCT).	Completed	NCT00143312	Phase 4	voriconazole
16	Population Pharmacokinetic Analysis of Caspofungin in Overweight and Obese Volunteers	Completed	NCT01062165	Phase 4	Caspofungin
17	A Multicenter Open-Label Study to Evaluate the Safety and Efficacy of DAB389IL-2 in Cutaneous T-Cell Lymphoma (CTCL) Patients Following Protocol 93-04-10, Protocol 93-04-11, or Protocol 92-04-01 or Who Meet the Requirements for Protocol 93-04-11 Except Have Biopsy-Documented CTCL That Does Not Express CD25	Completed	NCT00051012	Phase 4	ONTAK
18	A Multicenter Phase III Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy of Two Dose Levels of DAB389IL-2 (9 and 18 Mcg/kg/Day) in Cutaneous T-Cell Lymphoma (CTCL) Patients With Stage Ia-III Disease Who, Following Less Than or Equal to 3 Previous Therapies, Have Recurrent or Persistent Disease That Has Been Biopsy-Documented to Express CD25	Completed	NCT00050999	Phase 4	ONTAK
19	Invasive Fungal Infection in Liver Transplant Recipients: A Randomized Double-Blind Trial Comparing AmBisome and Fluconazole in the High Risk Group and an Observational Cohort Study in the Low Risk	Completed	NCT00001107	Phase 4	Fluconazole;AmBisome
20	The Use of Antifungal Lock Therapy in Intestinal Failure and Other Patients	Completed	NCT00936910	Phase 4	amphotericin B liposomal (Ambisome)
21	Prediction of Itraconazole Oral Absorption From In Vitro Dissolution	Completed	NCT04035187	Phase 4	fast itraconazole tablet;medium itraconazole tablet;slow itraconazole tablet;oral itraconazole solution
22	Oral Nystatin Prophylaxis to Prevent Systemic Fungal Infection in Very Low Birth Weight Preterm Infants: a Randomized Controlled Trial	Completed	NCT03390374	Phase 4	Nystatin Oral
23	Pharmacokinetics of Posaconazole (Noxafil®) as Prophylaxis for Invasive Fungal Infections	Completed	NCT02805946	Phase 4	posaconazole
24	UVADEX Sterile Solution in Conjunction With the UVAR XTS Photopheresis System as an Interventional Therapy for the Treatment Of CTCL (Mycosis Fungoides) in Patients With TMN Classification Stage 1A, 1B, 2A	Completed	NCT00221039	Phase 4	Methoxsalen+ECP
25	Assessment Of Voriconazole Penetration Into The Brain By Fluorine-Magnetic Resonance Spectroscopy	Completed	NCT00300677	Phase 4	voriconazole
26	An Open, Prospective, Uncontrolled, Multi-Center Study To Evaluate The Efficacy And Safety Of Voriconazole In Chinese Subjects With Proven Or Probable Serious Invasive Fungal Infections	Completed	NCT00288197	Phase 4	voriconazole
27	Multicenter, Randomized, Open-label Clinical Trial to Compare Anidulafungin Versus Amphotericin B Safety in High Risk Hepatic Transplant Recipients	Completed	NCT01303549	Phase 4	Anidulafungin;Liposomal amphotericin B
28	Efficacy of Itraconazole as Secondary Prophylaxis in Patients Undergoing Allogeneic Stem Cell Transplantation or Chemotherapy With Prior Invasive Fungal Infection	Completed	NCT01198236	Phase 4	Itraconazole
29	A Randomized Open-Label Trial of Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome	Completed	NCT01200355	Phase 4	micafungin;posaconazole
30	A Prospective, Randomized Trial Comparing the Efficacy and Safety of Voriconazole Administered With Therapeutic Drug Monitoring vs. Standard Dosing	Completed	NCT01416025	Phase 4	Prospective TDM Arm
31	A Randomized, Parallel, Single-Dose Study to Evaluate the Pharmacokinetics of Two Different Formulation of Voriconazole 200mg Tablets in Healthy Adult Subjects	Completed	NCT02912156	Phase 4	Vaway FC Tablets 200mg (Voriconazole);VFEND FC Tablets 200mg (Voriconazole)
32	Clinical Efficacy and Safety of Itraconazole Injection/Oral Solution Sequential Therapy for Treatment of Invasive Pulmonary Fungal Infections	Completed	NCT01823289	Phase 4	Itraconazole
33	Randomized and Multicenter Clinical Trial to Evaluate the Effectiveness and Efficiency of a Voriconazole Preemptive Genotyping Strategy in Patients With Risk of Aspergillosis	Recruiting	NCT04238884	Phase 4	Voriconazole preemptive genotyping strategy;Voriconazole clinical practice
34	Pharmacokinetics Study of Posaconazole in Haematology Patients Receiving Standard of Care Treatment With Oral Posaconazole Prophylaxis for Invasive Fungal Infection	Recruiting	NCT03717623	Phase 4	Posaconazole pharmacokinetics
35	Prospective, Observational and Cohort Clinical Research on Clinical Efficacy and Safety of Different Doses of Micafungin Sodium for Injection in Prevention and Treatment of Fungal Infection in Patients With Hematological Tumors	Recruiting	NCT04738955	Phase 4	Micafungin Sodium
36	A SINGLE ARM, PROSPECTIVE, MULTI-CENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF ISAVUCONAZOLE FOR PRIMARY TREATMENT OF CHINESE PATIENTS WITH INVASIVE FUNGAL DISEASE (IFD) CAUSED BY ASPERGILLUS SPECIES OR OTHER FILAMENTOUS FUNGI	Not yet recruiting	NCT05630976	Phase 4	Isavuconazole
37	To Evaluate the Efficacy and Safety of Micafungin in Preventing Invasive Mycosis After Liver Transplantation	Not yet recruiting	NCT04728971	Phase 4	Micafungin Sodium 50 MG Injection;Caspofungin Acetate
38	Itraconazole in the Management of Superficial Fungal Infections in India. A Pilot Study	Terminated	NCT03923010	Phase 4	Itraconazole
39	Prospective, Randomized Multicentic to Compare PUVA+IFN Alpha 2a vs PUVA Alone in Mycosis Fungoides Stages Ia, Ib or IIa.	Terminated	NCT00630903	Phase 4	PUVA (8MOP + UVA) + IFN;PUVA (8-MOP + UVA)
40	A Multi-center, Open-label, Non-comparative Study to Evaluate the Safety and Efficacy of Micafungin Against Fungal Infections Caused by Candida Spp or Aspergillus Spp	Terminated	NCT02646800	Phase 4	Micafungin
41	ProphyALL - Pilot Study on Safety of Four Weekly Administrations of 7 mg/kg of Liposomal Amphotericin B (AmBisome®) in Antifungal Primary Prophylaxis Treatment of Elderly Patients With Acute Lymphoblastic Leukemia Undergoing Induction Chemotherapy Within the GMALL-Elderly Protocol	Terminated	NCT00386997	Phase 4	liposomal amphotericin B (AmBisome®)
42	A Pharmacokinetic Analysis of Posaconazole in the Plasma and Alveolar Compartment of Lung Transplant Recipients	Terminated	NCT01667107	Phase 4	Posaconazole;Calogen®
43	Comparison of Methotrexate Versus Interferon-alfa 2b on Efficacy, Safety and Quality of Life in Patients With Primary Cutaneous T-cell Lymphomas	Terminated	NCT02323659	Phase 4	Methotrexate;Interferon Alfa-2b
44	Open Label, Limited Access Protocol of Posaconazole in Invasive Fungal Infections Study PO2095	Terminated	NCT00177749	Phase 4	Posaconazole
45	Randomized, Open Label, Non-inferiority Study of Micafungin Versus Fluconazole for the Korean Prevention of Invasive Fungal Disease in Living Donor Liver Transplant Recipients	Unknown status	NCT01974375	Phase 3	micafungin;Fluconazole
46	Study Clinical, Multicenter, Phase III, to Evaluate the Efficacy and Safety of Tolnaftate Cream in the Treatment of Patients With Fungal Infections Like Tinea Foot, Tinea and Tinea Crural Body"	Unknown status	NCT01105013	Phase 3	Clotrimazole
47	Combination Treatment of 5% Natamycin and 1% Voriconazole in Fungal Keratitis: a Prospective Randomized Double Masked Clinical Trial	Unknown status	NCT03230058	Phase 2, Phase 3	Group 1 Natamycin 5% Suspension + voriconazole 1% eye drops; Group 2 Natamycin 5% Suspension + Vehicle eye drops
48	Efficacy, Safety and Pharmacokinetics of SPK-843 in the Treatment of Pulmonary Mycosis. Open Label Phase III Clinical Study	Unknown status	NCT01125644	Phase 3	SPK-843
49	Efficacy of Doxycycline in the Treatment of Early Stages of Mycosis Fungoides: A Randomized Controlled Trial	Unknown status	NCT03454945	Phase 3	Vibramycin
50	Open-Label, Non-Comparative Protocol for the Emergency Use of Voriconazole in Patients With Life Threatening, Invasive Mycoses Who Are Failing on Currently Available Antifungal Agents	Completed	NCT00015665	Phase 3	Voriconazole

Search NIH Clinical Center for Fungal Infectious Disease

Cochrane evidence based reviews: mycoses

Sources

Genetic Tests for Fungal Infectious Disease

Sources

Anatomical Context for Fungal Infectious Disease

Organs/tissues related to Fungal Infectious Disease:

MalaCards : Skin, Liver, T Cells, Bone Marrow, Myeloid, Lung, Eye

Sources

Publications for Fungal Infectious Disease

Articles related to Fungal Infectious Disease:

(show top 50) (show all 16232)

#	Title	Authors	PMID	Year
1	Ni/Ni(OH)2-rGO nanocomposites sensor for the detection of long forgotten mycotoxin, xanthomegnin. ⁶²	Swetha PDP...Prasad KS	36179558	2023
2	Treatment of the Candida subspecies Candida albicans and Candida parapsilosis with two far-UVC sources to minimise mycoses in clinical practice. ⁶²	Schleusener J...Meinke MC	35986595	2023
3	Cytomorphology of Deep Mycoses in Dogs and Cats. ⁶²	Dehghanpir SD	36270845	2023
4	Moving mycoses up the global agenda. ⁶²	The Lancet Global Health	36400070	2022
5	The Impact of Paracoccidioides spp Infection on Central Nervous System Cell Junctional Complexes. ⁶²	de Almeida SM...de Noronha L	35922705	2022
6	Sporotrichosis in dogs: epidemiological and clinical-therapeutic profile and the emergence of itraconazole-resistant isolates. ⁶²	Baes Pereira S...Pascoti Bruhn FR	36455616	2022
7	Update of the Epidemiology of the Sporotrichosis Epidemic in the state of Rio Grande do Sul, Brazil. ⁶²	Munhoz LS...Xavier MO	35833311	2022
8	Cutaneous chromoblastomycosis mimicking melanoma in a renal transplant recipient. ⁶²	Kim JSTW...Ogawa MM	36393996	2022
9	Current situation of endemic mycosis in the Americas and the Caribbean: Proceedings of the first international meeting on endemic mycoses of the Americas (IMEMA). ⁶²	Caceres DH...Giusiano G	35971917	2022
10	Invasive mucormycosis in a tertiary care hospital in the western region of Saudi Arabia: 11-year retrospective chart review from 2009 to 2019. ⁶²	Almarhabi H...Althaqafi A	36403403	2022
11	Pharmacokinetics of fluconazole after oral administration to healthy beagle dogs. ⁶²	Choi Y...Kang BT	36000582	2022
12	Atorvastatin-loaded emulsomes foam as a topical antifungal formulation. ⁶²	Eita AS...Khalil IA	36465276	2022
13	[Chronic pulmonary mycosis due to Paracoccidioides brasiliensis]. ⁶²	Asencio Egea MA...Huertas Vaquero M	36260755	2022
14	Scedosporium apiospermum mediastinitis in an orthotopic heart transplant recipient. ⁶²	Saini V...Bhanot N	36277499	2022
15	Changes of the gene expression in silkworm larvae and Cordyceps militaris at late stages of the pathogenesis. ⁶²	Kato T...Park EY	36116100	2022
16	Pathogenicity & virulence of Histoplasma capsulatum - A multifaceted organism adapted to intracellular environments. ⁶²	Valdez AF...Nosanchuk JD	36266777	2022
17	Interleukin (IL)-33 immunobiology in asthma and airway inflammatory diseases. ⁶²	Gaurav R...Poole JA	34928757	2022
18	Double CD4/CD8-Positive, Nonpoikilodermic Mycosis Fungoides Expressing CD56 in a Young Man. ⁶²	Santonja C...Rodriguez-Pinilla SM	35925554	2022
19	Syringotropic Mycosis Fungoides: A Variant of Folliculotropic or a Distinct Subtype of Adnexotropic Mycosis Fungoides? ⁶²	Nussbaum D...Prussick R	36468959	2022
20	Mycosis fungoides in pediatric population: comprehensive review on epidemiology, clinical presentation, and management. ⁶²	Kothari R...Goldust M	35193164	2022
21	Maintenance and Concomitant Therapy Use with Chlormethine Gel Among Patients with Stage IA/IB Mycosis Fungoides-Type Cutaneous T-Cell Lymphoma (MF-CTCL): A Real-World Evidence Study. ⁶²	Querfeld C...Geskin LJ	36284059	2022
22	A case of erythrodermic mycosis fungoides responding to upadacitinib. ⁶²	Castillo DE...Kerdel F	36411841	2022
23	A cross-sectional analysis of Google images of mycosis fungoides: is dark skin adequately represented? ⁶²	Alexander-Savino CV...Bowers EV	36468820	2022
24	Response to "Mycosis fungoides in pediatric population: comprehensive review on epidemiology, clinical presentation, and management". ⁶²	Turkmen D...Alan S	35965350	2022
25	Correction to: Efficacy of narrowband UVB phototherapy in early‑stage mycosis fungoides in Iranian patients. ⁶²	Kebria AS...Shirafkan H	35881209	2022
26	Expression pattern and diagnostic utility of BCL11B in mature T- and NK-cell neoplasms. ⁶²	Fang H...Wang W	35864006	2022
27	Primary cutaneous peripheral T-cell lymphomas with a T-follicular helper phenotype: an integrative clinical, pathological and molecular case series study. ⁶²	Wang L...Ortonne N	35895386	2022
28	Itch in patients with cutaneous T-cell lymphoma as a quality of life indicator. ⁶²	Ottevanger R...Quint KD	36147217	2022
29	Evaluation of clonality from multiple anatomic sites in canine epitheliotropic T cell lymphoma. ⁶²	Keating MK...Moore PF	35876313	2022
30	Cutaneous Lymphocyte Antigen Is a Potential Therapeutic Target in Cutaneous T-Cell Lymphoma. ⁶²	Peru S...Poglio S	35850209	2022
31	Influenza vaccination is associated with a reduced risk of invasive aspergillosis in high-risk individuals in Taiwan: a population-based cohort study. ⁶²	Chen YJ...Chan TC	36469743	2022
32	Distinguishing Invasive from Chronic Pulmonary Infections: Host Pentraxin 3 and Fungal Siderophores in Bronchoalveolar Lavage Fluids. ⁶²	Dobias R...Havlicek V	36422015	2022
33	Susceptibility and characteristics of infections in patients with glucocorticoid excess or insufficiency: the ICARO tool. ⁶²	Minnetti M...Isidori AM	36102827	2022
34	Impact of revised EORTC/MSGERC 2020 criteria on diagnosis and prognosis of invasive pulmonary aspergillosis in patients with hematological malignancies undergoing bronchoscopy. ⁶²	Acet-Ozturk NA...Ali R	35738036	2022
35	Treatments of refractory eosinophilic lung diseases with biologics. ⁶²	Asano K...Kamide Y	36333218	2022
36	Exploring the most visible websites on cutaneous T-cell lymphoma-revealing limited quality of patient health information on the internet. ⁶²	Ozistanbullu D...Meissner M	35842932	2022
37	A novel mouse model of cutaneous T-cell lymphoma revealed the combined effect of mogamulizumab with psoralen and ultraviolet a therapy. ⁶²	Nakahashi K...Mori K	35801380	2022
38	Development of indirect ELISA and its evaluation in comparison with KOH hydrolysis and fungal culture for the immuno diagnosis of Trichophyton rubrum and Trichophyton mentagrophytes infection in humans. ⁶²	Aruna GL...Ramalingappa B	35907501	2022
39	Performance of the JF5-Based Galactomannoprotein EIA Compared to the Lateral Flow Device and the Galactomannan EIA in Serum and Bronchoalveolar Lavage Fluid. ⁶²	Aerts R...Maertens J	36214562	2022
40	Anti-Aspergillus fumigatus IgG in patients with bronchiectasis and its relationship with clinical outcome. ⁶²	Trapaga MR...Xavier MO	36434134	2022
41	Using infrared spectroscopy of serum and chemometrics for diagnosis of paracoccidioidomycosis. ⁶²	Koehler A...Corbellini VA	36113324	2022
42	Nascent Nanoformulations as an Insight Into the Limitations of the Conventional Systemic Antifungal Therapies. ⁶²	Kaur M...Jain SK	36443967	2022
43	Preliminary Investigation about Aspergillus spp. Spread in Umbrian Avian Farms. ⁶²	Cruciani D...Agnetti F	36422034	2022
44	Osteoarticular Mycoses. ⁶²	Gamaletsou MN...International Consortium for Osteoarticular Mycoses	36448782	2022
45	The first report of tinea nigra from Iran. ⁶²	Kelarestaghi A...Khodavaisy S	36276912	2022
46	Cutaneous T cell lymphoma treated with mogamulizumab monotherapy and mogamulizumab plus etoposide combined therapy: A real-world case series. ⁶²	Amagai R...Fujimura T	36161437	2022
47	Risk of Non-cutaneous Cancers in Individuals with Basal Cell Carcinoma: A Population-based Cohort Study. ⁶²	Kuru H...Huilaja L	36448850	2022
48	Mogamulizumab and bexarotene are a promising association for the treatment of advanced cutaneous T-cell lymphomas: a case series. ⁶²	Teoli M...Ardigo M	36394762	2022
49	Targeting the CD47-SIRPα Axis: Present Therapies and the Future for Cutaneous T-cell Lymphoma. ⁶²	Xiao A...Akilov OE	36429020	2022
50	Single-cell analyses reveal novel molecular signatures and pathogenesis in cutaneous T cell lymphoma. ⁶²	Xue X...Zhang F	36400759	2022

Sources

Genes for Fungal Infectious Disease

Genes related to Fungal Infectious Disease (0 elite genes):

(show top 50) (show all 51)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	CCR6	C-C Motif Chemokine Receptor 6	Protein Coding	12.14	DISEASES inferred ¹⁴ ¹⁴
2	CD4	CD4 Molecule	Protein Coding	9.4	DISEASES inferred ¹⁴
3	CLEC7A	C-Type Lectin Domain Containing 7A	Protein Coding	8.9	DISEASES inferred ¹⁴
4	CARD9	Caspase Recruitment Domain Family Member 9	Protein Coding	8.43	DISEASES inferred ¹⁴
5	AIRE	Autoimmune Regulator	Protein Coding	8.3	DISEASES inferred ¹⁴
6	IL17A	Interleukin 17A	Protein Coding	8.29	DISEASES inferred ¹⁴
7	CLEC6A	C-Type Lectin Domain Containing 6A	Protein Coding	8.18	DISEASES inferred ¹⁴
8	CD8A	CD8a Molecule	Protein Coding	8.04	DISEASES inferred ¹⁴
9	CYP51A1	Cytochrome P450 Family 51 Subfamily A Member 1	Protein Coding	8.04	DISEASES inferred ¹⁴
10	TNF	Tumor Necrosis Factor	Protein Coding	7.98	DISEASES inferred ¹⁴
11	IL10	Interleukin 10	Protein Coding	7.88	DISEASES inferred ¹⁴
12	IL6	Interleukin 6	Protein Coding	7.84	DISEASES inferred ¹⁴
13	H2AC18	H2A Clustered Histone 18	Protein Coding	7.82	DISEASES inferred ¹⁴ ¹⁴
14	CRP	C-Reactive Protein	Protein Coding	7.71	DISEASES inferred ¹⁴
15	IL4	Interleukin 4	Protein Coding	7.7	DISEASES inferred ¹⁴
16	ICOSLG	Inducible T Cell Costimulator Ligand	Protein Coding	7.7	DISEASES inferred ¹⁴ ¹⁴
17	IL1B	Interleukin 1 Beta	Protein Coding	7.6	DISEASES inferred ¹⁴
18	IL17RA	Interleukin 17 Receptor A	Protein Coding	7.57	DISEASES inferred ¹⁴
19	TLR2	Toll Like Receptor 2	Protein Coding	7.56	DISEASES inferred ¹⁴
20	IL17F	Interleukin 17F	Protein Coding	7.56	DISEASES inferred ¹⁴
21	CSF2	Colony Stimulating Factor 2	Protein Coding	7.49	DISEASES inferred ¹⁴
22	CLEC4E	C-Type Lectin Domain Family 4 Member E	Protein Coding	7.45	DISEASES inferred ¹⁴
23	ALB	Albumin	Protein Coding	7.4	DISEASES inferred ¹⁴
24	STAT1	Signal Transducer And Activator Of Transcription 1	Protein Coding	7.38	DISEASES inferred ¹⁴
25	CXCL8	C-X-C Motif Chemokine Ligand 8	Protein Coding	7.35	DISEASES inferred ¹⁴
26	IFNG	Interferon Gamma	Protein Coding	7.32	DISEASES inferred ¹⁴
27	IL2	Interleukin 2	Protein Coding	7.28	DISEASES inferred ¹⁴
28	IL5	Interleukin 5	Protein Coding	7.26	DISEASES inferred ¹⁴
29	CSF3	Colony Stimulating Factor 3	Protein Coding	7.24	DISEASES inferred ¹⁴
30	TLR4	Toll Like Receptor 4	Protein Coding	7.22	DISEASES inferred ¹⁴
31	CBS	Cystathionine Beta-Synthase	Protein Coding	7.15	DISEASES inferred ¹⁴
32	PLB1	Phospholipase B1	Protein Coding	7.11	DISEASES inferred ¹⁴
33	IL13	Interleukin 13	Protein Coding	7.1	DISEASES inferred ¹⁴
34	POLR2B	RNA Polymerase II Subunit B	Protein Coding	7.09	DISEASES inferred ¹⁴
35	ECE1	Endothelin Converting Enzyme 1	Protein Coding	7.05	DISEASES inferred ¹⁴
36	SYK	Spleen Associated Tyrosine Kinase	Protein Coding	7.01	DISEASES inferred ¹⁴
37	IL12RB1	Interleukin 12 Receptor Subunit Beta 1	Protein Coding	6.97	DISEASES inferred ¹⁴
38	DOCK8	Dedicator Of Cytokinesis 8	Protein Coding	6.94	DISEASES inferred ¹⁴
39	IL17RC	Interleukin 17 Receptor C	Protein Coding	6.94	DISEASES inferred ¹⁴
40	STAT3	Signal Transducer And Activator Of Transcription 3	Protein Coding	6.88	DISEASES inferred ¹⁴
41	CLEC4D	C-Type Lectin Domain Family 4 Member D	Protein Coding	6.83	DISEASES inferred ¹⁴
42	MYD88	MYD88 Innate Immune Signal Transduction Adaptor	Protein Coding	6.81	DISEASES inferred ¹⁴
43	TLR9	Toll Like Receptor 9	Protein Coding	6.79	DISEASES inferred ¹⁴
44	GFM1	G Elongation Factor Mitochondrial 1	Protein Coding	6.77	DISEASES inferred ¹⁴
45	CD209	CD209 Molecule	Protein Coding	6.76	DISEASES inferred ¹⁴
46	ATP12A	ATPase H+/K+ Transporting Non-Gastric Alpha2 Subunit	Protein Coding	6.75	DISEASES inferred ¹⁴
47	ATP4A	ATPase H+/K+ Transporting Subunit Alpha	Protein Coding	6.74	DISEASES inferred ¹⁴
48	PIGW	Phosphatidylinositol Glycan Anchor Biosynthesis Class W	Protein Coding	6.73	DISEASES inferred ¹⁴
49	IL1A	Interleukin 1 Alpha	Protein Coding	6.71	DISEASES inferred ¹⁴
50	DEFB4A	Defensin Beta 4A	Protein Coding	6.7	DISEASES inferred ¹⁴

Sources

Variations for Fungal Infectious Disease

Sources

Expression for Fungal Infectious Disease

Search GEO for disease gene expression data for Fungal Infectious Disease.

Sources

Pathways for Fungal Infectious Disease

Pathways related to Fungal Infectious Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 55)

#	Super pathways	Score	Top Affiliating Genes
1	Innate Immune System ⁶⁶ Show member pathways Immune System ⁶⁶ Neutrophil degranulation ⁶⁶	13.89	TNF TLR2 IL6 IL4 IL1B IL17RA
2	ERK Signaling ⁶⁴ Show member pathways ILK Signaling ⁶⁴ MAPK Signaling ⁶⁴ Molecular Mechanisms of Cancer ⁶⁴ Rho Family GTPases ⁶⁴	13.83	TNF IL6 IL4 IL1B IL17RA IL17A
3	MIF Mediated Glucocorticoid Regulation ⁶⁴ Show member pathways all-trans-Retinoic Acid Signaling in Brain ⁶⁴ Endothelin-1 Signaling Pathway ⁶⁴ Glucocorticoid Receptor Signaling ⁶⁴ IL-6 Pathway ⁶⁴ MIF Regulation of Innate Immune Cells ⁶⁴ NFAT Signaling and Lymphocyte Interactions ⁶⁴ Overview of proinflammatory and profibrotic mediators ⁷⁴ PEDF Induced Signaling ⁶⁴ PGC1Alpha Pathway ⁶⁴ RAR-Gamma-RXR-Alpha Degradation ⁶⁴ STAT3 Pathway ⁶⁴	13.66	TNF IL6 IL4 IL1B IL17RA IL17F
4	Akt Signaling ⁶⁴ Show member pathways p38 Signaling ⁶⁴ Tec Kinases Signaling ⁶⁴	13.44	CCR6 CD4 IL10 IL17A IL17RA IL1B
5	Cytokine Signaling in Immune system ⁶⁶ Show member pathways Signaling by Interleukins ⁶⁶	13.36	TNF IL6 IL4 IL1B IL17RA IL17F
6	PAK Pathway ⁶⁴ Show member pathways Antioxidant Action of Vitamin-C ⁶⁴ Epithelial Adherens Junctions ⁶⁴	13.33	TNF IL6 IL4 IL1B IL17RA IL17A
7	IL-1 Family Signaling Pathways ⁶⁵ Show member pathways IL1 signaling pathway ⁶⁷ Immune response IL-1 signaling pathway ²² Interleukin-1 (IL-1) structural pathway ⁷⁴ Interleukin-33 signaling ⁶⁶ Interleukin-36 pathway ⁶⁶ Mucin expression in CF via TLRs, EGFR signaling pathways ²² Pathogen or Damage-activated C-Type Lectin Receptor Signaling Pathways ⁶⁵	12.68	TNF TLR2 IL6 IL1B CLEC7A CLEC6A
8	Overview of interferons-mediated signaling pathway ⁷⁴ Show member pathways all-trans-Retinoic Acid Mediated Apoptosis ⁶⁴ Cytokine Network ⁶⁴ Immune response IFN alpha/beta signaling pathway ²² Interferon alpha/beta signaling ⁶⁶ Jak/STAT Signaling Pathway ⁶⁵ Regulation of IFNA/IFNB signaling ⁶⁶ Type III interferon signaling ⁷⁴	12.67	TNF IL6 IL4 IL1B IL17A IL10
9	NF-kappaB Signaling ³	12.65	TNF TLR2 IL4 IL1B IL17A IL10
10	Immune response IL-23 signaling pathway ²² Show member pathways Angiopoietin receptor Tie2-mediated signaling ⁶¹ Angiopoietin-TIE2 Signaling ⁶⁴ Development Angiopoietin - Tie2 signaling ²² Development PDGF signaling via STATs and NF-kB ²² IL23-mediated signaling events ⁶¹ Immune response IL-10 signaling pathway ²² RAC1/PAK1/p38/MMP2 pathway ⁷⁴	12.64	TNF IL6 IL1B IL17F IL17A IL10
11	Toll-Like receptor Signaling Pathways ⁶⁵ Show member pathways Inflammasome Activation Pathways ⁶⁵ Nanomaterial-induced inflammasome activation ⁷⁴ NOD-like Receptor Signaling Pathways ⁶⁵ TLR4 signaling and tolerance ⁷⁴ Toll-Like Receptors Pathway ⁶⁴	12.56	TNF TLR2 IL6 IL1B CARD9
12	Bacterial infections in CF airways ²² Show member pathways Altered glycosylation of MUC1 in tumor microenvironment ⁷⁴ IL-1 beta-dependent CFTR expression ²² IL1-mediated signaling events ⁶¹ Immune response Bacterial infections in normal airways ²² Immune response TLR signaling pathways ²² NTHi-Induced Signaling ⁶⁴ Signal transduction through IL1R ⁷⁴	12.47	IL1B IL4 IL6 TLR2 TNF
13	CLEC7A (Dectin-1) signaling ⁶⁶ Show member pathways Alternative NF-kappaB pathway ⁶¹ CLEC7A/inflammasome pathway ⁶⁶ C-type lectin receptors (CLRs) ⁶⁶	12.43	IL1B CLEC7A CLEC6A CARD9
14	IL-17 Family Signaling Pathways ⁶⁵ Show member pathways IL17 signaling pathway ⁶⁷ IL-17 signaling pathway ⁷⁴ Mucin expression in CF via IL-6, IL-17 signaling pathways ²²	12.35	TNF TLR2 IL6 IL17RA IL17F IL17A
15	T-cell activation SARS-CoV-2 ⁷⁴ Show member pathways T-cell antigen receptor (TCR) pathway during Staphylococcus aureus infection ⁷⁴	12.22	TNF IL4 IL17A IL10 CD8A CD4
16	Sudden infant death syndrome (SIDS) susceptibility pathways ⁷⁴	12.19	TNF IL6 IL1B IL10
17	Neuroinflammation and glutamatergic signaling ⁷⁴	12.17	TNF IL6 IL4 IL1B IL10
18	Hematopoietic Stem Cells and Lineage-specific Markers ⁶⁵	12.09	CD4 CD8A IL10 IL4 IL6 TNF
19	Spinal cord injury ⁷⁴	12.04	TNF IL6 IL4 IL1B
20	IL12-mediated signaling events ⁶¹ Show member pathways Immune response IL-12-induced IFN-gamma production ²²	12.02	IL4 IL1B CD8A CD4
21	Interleukin-4 and Interleukin-13 signaling ⁶⁶	12.01	TNF IL6 IL4 IL1B IL17F IL17A
22	Allograft rejection ⁷⁴	11.96	TNF IL4 IL1B IL17A IL10
23	Cytokine production by Th17 cells in CF (Mouse model) ²² Show member pathways Cytokine production by Th17 cells in CF ²²	11.93	IL6 IL17RA IL17F IL17A
24	Network map of SARS-CoV-2 signaling pathway ⁷⁴ Show member pathways Pathogenesis of SARS-CoV-2 mediated by nsp9-nsp10 complex ⁷⁴	11.83	IL6 CRP CD8A CD4
25	Extrafollicular B cell activation by SARS-CoV-2 ⁷⁴	11.82	TNF IL6 IL4 IL10 ICOSLG CRP
26	Th17 cell differentiation pathway ⁷⁴	11.79	IL6 IL4 IL1B IL17F IL17A CD4
27	Dendritic Cells Developmental Lineage Pathway ⁶⁵	11.78	TNF IL6 IL1B IL17RA IL10 CD8A
28	Burn wound healing ⁷⁴	11.77	TNF IL6 IL1B
29	Acute viral myocarditis ⁷⁴	11.76	IL6 IL10 CD4
30	IL27-mediated signaling events ⁶¹ Show member pathways IL12 signaling pathway ⁶⁷ Th1 Differentiation ⁶⁵	11.76	TNF TLR2 IL6 IL1B IL17F IL17A
31	Lung fibrosis ⁷⁴	11.74	TNF IL6 IL4 IL1B
32	AP-1 transcription factor network ⁶¹	11.73	IL6 IL4 IL10
33	IL 10 signaling pathway ⁶⁷	11.73	IL10 IL1B IL6 TNF
34	Inflammatory bowel disease signaling ⁷⁴ Show member pathways Ulcerative colitis signaling ⁷⁴	11.7	IL10 IL17F IL4 IL6 TLR2 TNF
35	Photodynamic therapy-induced NF-kB survival signaling ⁷⁴ Show member pathways Immune response MIF-mediated glucocorticoid regulation ²²	11.68	TNF IL6 IL1B
36	miRNAs involvement in the immune response in sepsis ⁷⁴	11.67	TNF IL6 IL10
37	THC Differentiation Pathway ⁶⁴	11.59	TNF IL4 IL10 CD4
38	Interleukin-10 signaling ⁶⁶	11.59	IL10 IL1B IL6 TNF
39	MSP-RON Signaling ⁶⁴	11.56	TNF TLR2 IL1B
40	Th2 Differentiation ⁶⁵	11.53	CD4 IL10 IL4
41	Transcription_Role of VDR in regulation of genes involved in osteoporosis ²²	11.52	TNF IL6 IL1B
42	Th17 Differentiation ⁶⁵ Show member pathways IL-21 Signaling and its Primary Biological Effects in Different Immune Cell Types ⁶⁵	11.52	TLR2 IL6 IL4 IL1B IL17RA IL17F
43	IL-10 Pathway ⁶⁴	11.45	TNF IL6 IL1B IL10
44	Development and heterogeneity of the ILC family ⁷⁴	11.43	TNF IL6 IL4 IL1B IL17A
45	Prostaglandin signaling ⁷⁴	11.36	TNF IL6 IL1B IL17F IL17A
46	Antiviral and anti-inflammatory effects of Nrf2 on SARS-CoV-2 pathway ⁷⁴	11.33	TNF IL6 IL1B
47	Cytokines and inflammatory response ⁷⁴	11.26	CD4 IL10 IL1B IL4 IL6 TNF
48	Immune infiltration in pancreatic cancer ⁷⁴	11.17	TNF IL6 IL4 IL17F IL17A IL10
49	LDL- influence on CD14 and TLR4 ⁷⁴	11.16	IL6 IL1B IL10
50	Innate Lymphoid Cells Differentiation ⁶⁵	11.13	TNF IL4 IL1B IL17A IL10 CD8A

Sources

GO Terms for Fungal Infectious Disease

Cellular components related to Fungal Infectious Disease according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	external side of plasma membrane	GO:0009897	9.47	TNF IL17A ICOSLG CLEC6A CD8A CD4

Biological processes related to Fungal Infectious Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 56)

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of transcription by RNA polymerase II	GO:0045944	10.64	AIRE IL10 IL17A IL17F IL1B IL4
2	positive regulation of gene expression	GO:0010628	10.5	CLEC7A CRP IL1B IL4 IL6 TLR2
3	innate immune response	GO:0045087	10.46	TLR2 IL17RA IL17F IL17A CRP CLEC7A
4	inflammatory response	GO:0006954	10.39	CLEC7A CRP IL17A IL17F IL17RA IL1B
5	adaptive immune response	GO:0002250	10.37	CARD9 CD4 CD8A CLEC6A ICOSLG IL17A
6	positive regulation of I-kappaB kinase/NF-kappaB signaling	GO:0043123	10.34	TNF IL1B CLEC7A CLEC6A CD4 CARD9
7	positive regulation of DNA-binding transcription factor activity	GO:0051091	10.3	TNF IL6 IL1B IL10 CLEC7A
8	positive regulation of inflammatory response	GO:0050729	10.29	TNF TLR2 IL1B IL17RA
9	defense response to Gram-negative bacterium	GO:0050829	10.27	IL6 IL17F IL17A CD4
10	positive regulation of tumor necrosis factor production	GO:0032760	10.27	CARD9 CLEC7A IL17A IL6 TLR2
11	positive regulation of NF-kappaB transcription factor activity	GO:0051092	10.25	TNF TLR2 IL6 IL1B CLEC7A CARD9
12	positive regulation of interleukin-1 beta production	GO:0032731	10.24	CLEC7A IL17A IL6 TNF
13	humoral immune response	GO:0006959	10.23	TNF IL6 CCR6 AIRE
14	positive regulation of interleukin-12 production	GO:0032735	10.2	TLR2 IL17A CLEC7A
15	positive regulation of nitric oxide biosynthetic process	GO:0045429	10.19	TNF IL1B CLEC7A
16	lipopolysaccharide-mediated signaling pathway	GO:0031663	10.19	IL1B TLR2 TNF
17	positive regulation of interleukin-10 production	GO:0032733	10.19	TLR2 IL6 IL4 CLEC7A
18	positive regulation of receptor signaling pathway via JAK-STAT	GO:0046427	10.18	TNF IL6 IL10
19	regulation of I-kappaB kinase/NF-kappaB signaling	GO:0043122	10.18	TNF IL1B CLEC7A
20	positive regulation of interleukin-2 production	GO:0032743	10.18	CD4 CLEC7A IL1B
21	defense response to fungus	GO:0050832	10.18	CLEC6A IL17A IL17RA
22	positive regulation of interleukin-8 production	GO:0032757	10.18	CLEC7A IL1B IL6 TLR2 TNF
23	immune response	GO:0006955	10.18	TNF TLR2 IL6 IL4 IL1B IL17A
24	liver regeneration	GO:0097421	10.16	TNF IL6 IL10
25	T cell activation	GO:0042110	10.16	IL4 ICOSLG CLEC7A CD8A CD4
26	defense response to Gram-positive bacterium	GO:0050830	10.16	CARD9 CRP IL17A IL17F IL1B IL6
27	microglial cell activation	GO:0001774	10.15	TNF TLR2 IL4
28	negative regulation of neurogenesis	GO:0050768	10.15	IL1B IL6 TNF
29	positive regulation of cytokine production	GO:0001819	10.14	TNF IL1B IL17F IL10 CLEC6A CARD9
30	antifungal innate immune response	GO:0061760	10.12	CLEC7A CLEC6A CARD9
31	positive regulation of glial cell proliferation	GO:0060252	10.12	TNF IL6 IL1B
32	positive regulation of heterotypic cell-cell adhesion	GO:0034116	10.1	TNF IL1B IL10
33	positive regulation of T-helper 17 type immune response	GO:2000318	10.09	CARD9 CLEC6A CLEC7A
34	positive regulation of neuroinflammatory response	GO:0150078	10.08	IL1B IL6 TNF
35	negative regulation of lipid storage	GO:0010888	10.07	TNF IL6 CRP
36	immune system process	GO:0002376	10.07	CARD9 CD4 CD8A CLEC6A CLEC7A ICOSLG
37	positive regulation of chemokine production	GO:0032722	10.06	TNF TLR2 IL6 IL1B CARD9 AIRE
38	interleukin-17-mediated signaling pathway	GO:0097400	10.05	IL17RA IL17F IL17A
39	positive regulation of mononuclear cell migration	GO:0071677	10.02	TNF IL4
40	negative regulation of cytokine production involved in immune response	GO:0002719	10.02	TNF IL10
41	cell activation	GO:0001775	10.02	TNF TLR2 CLEC7A
42	positive regulation of interleukin-23 production	GO:0032747	10.02	IL17RA IL17A CLEC7A
43	positive regulation of fever generation	GO:0031622	10.01	TNF IL1B
44	regulation of interleukin-8 production	GO:0032677	10.01	IL17F CRP
45	vascular endothelial growth factor production	GO:0010573	10.01	TNF IL6 IL1B
46	fibroblast activation	GO:0072537	10	IL17RA IL17A
47	regulation of isotype switching	GO:0045191	9.99	IL4 IL10
48	sequestering of triglyceride	GO:0030730	9.99	TNF IL1B
49	positive regulation of calcidiol 1-monooxygenase activity	GO:0060559	9.98	TNF IL1B
50	regulation of interleukin-2 production	GO:0032663	9.97	IL17F CARD9